Reporting owner · CIK 0001931825
Column Group Opportunity III, LP
Visual SEC Form 4 history across 3 companies, 23 transactions and 4 filings.
10%Eikon Therapeutics, Inc.
Open-market mix
100%buys
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for some of their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Mar 25
—
Jan 26
$300.3K
Feb 26
$38.1M
Sep 26
$1M
Transaction texture
Ownership and ticket size
Average P/S size—
Median P/S size—
Direct0
Indirect23
Sep 03, 2026buy
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
Latest transaction
buy at Eikon Therapeutics, Inc. on Sep 03, 2026 valued at $1,031,045.
Review SEC filingLatest sale
No open-market insider sale is available.
Associated companies
Visual map of known reporting history
| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| TNYA | Column Group Opportunity III, LP | 10% | buy | 17.8M | — | P | — | 03/08/2025 | 03/05/2025 | |
| TNYA | Column Group Opportunity III, LP | 10% | buy | 35.7M | — | P | — | 03/08/2025 | 03/05/2025 | |
| TNYA | Column Group Opportunity III, LP | 10% | buy | 35.7M | $2.49B | P | — | 03/08/2025 | 03/05/2025 |
Column Group Opportunity III, LP Insider Activity FAQ
SEC Form 4 context
Who is Column Group Opportunity III, LP?
Column Group Opportunity III, LP is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001931825.
Which companies has Column Group Opportunity III, LP reported transactions for?
Eikon Therapeutics, Inc., Surrozen, Inc./DE, Tenaya Therapeutics, Inc.
When was Column Group Opportunity III, LP's latest insider buy?
buy at Eikon Therapeutics, Inc. on Sep 03, 2026 valued at $1,031,045.
When was Column Group Opportunity III, LP's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.